Afucosylated-anti–PD-L1-has-superior-activity-.jpg

SVE NEWS & SCIENCE.ORG Sharing Series — Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy

Tweaking the scaffold Immune checkpoint blockade using anti–PD-L1 monoclonal antibodies (mAbs) is used for treatment of multiple cancers. Whether these mAbs have the optimal Fc scaffold to induce Fc-mediated effector functions is unclear. Here, Cohen-Saban et al. investigate how FcγR engagement by

    Top